Obesity – Page 13

, Eli Lilly, Novo Nordisk, Roche, Obesity drugs, Weight-loss drug market, Stock market, Pharmaceutical competition, GLP-1 therapy, CT-996, Zepbound, Wegovy,

Eli Lilly’s Tirzepatide Approved in China for Weight Loss Management Amid Growing Obesity Concerns

11 months ago talkbio0Tagged agonists, China, Diabetes, Eli, Eli Lilly, Glucagon-Like Peptide 1, Mounjaro, Nordisk, Obesity, semaglutide, tirzepatide, Wegovy, Weight Loss, Zepbound

Eli Lilly, Tirzepatide, Weight Loss, China, Obesity, Novo Nordisk, GLP-1 Agonists, Diabetes, Mounjaro, Zepbound, Semaglutide, Wegovy

Roche Continues to Reap Rewards of Carmot Buyout with Strong Early GLP-1 Data

11 months ago talkbio0Tagged Carmot, CT-388, Diabetes, Drug Industry, GLP-1/GIP receptor agonist, Obesity, Roche (company)

Roche, Carmot Therapeutics, GLP-1/GIP receptor agonist, CT-388, obesity treatment, weight loss, diabetes, pharmaceutical industry

CordenPharma Invests €900M in Peptide Manufacturing Expansion to Meet Rising Demand for GLP-1 Medications

11 months ago talkbio0Tagged CordenPharma, Diabetes, Drug Industry, expansion, Glucagon-Like Peptide 1, Investments, Obesity, Peptides

CordenPharma, GLP-1, peptide manufacturing, expansion, investment, diabetes, obesity, pharmaceutical industry

Pfizer Advances Development of Once-Daily Oral GLP-1 Receptor Agonist Danuglipron for Obesity Treatment

11 months ago talkbio0Tagged Clinical Trials, Danuglipron, Drug Formulation Process, Glucagon-Like Peptide-1 Receptor, Obesity, once-daily, Pfizer, Weight Loss Medication

Pfizer, Danuglipron, GLP-1 Receptor Agonist, Obesity Treatment, Once-Daily Formulation, Clinical Trials, Weight Loss Medication

Zealand Raises $1 Billion to Advance Amylin Obesity Drug and Seek Partnership

12 months ago talkbio0Tagged Amylin, Billion Raise, Obesity, Partnership, Weight Loss, Zealand Pharma

Zealand Pharma, Obesity, Amylin, Weight Loss, $1 Billion Raise, Partnership

Novo Nordisk Invests $4.1 Billion in New US Manufacturing Site, Abandoning Irish Plans

12 months ago talkbio0Tagged Clayton, fill-finish facility, Irish, Irish (ethnic group), manufacturing site, Nordisk, North Carolina, Obesity, U.S.

Novo Nordisk, US manufacturing site, obesity drugs, fill-finish facility, Clayton, NC, Irish build